Two of the most discussed compounds in metabolic and endurance research don’t just work individually — when combined, SLU-PP-332 and Cardarine (GW-501516) target overlapping but distinct pathways in a way that has caught serious attention from the research community. This article breaks down what the science currently says about each compound, the rationale for combining them, and key considerations for researchers exploring this stack.
What Is SLU-PP-332?
SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptors alpha, beta, and gamma (ERRα, ERRβ, ERRγ) — a family of nuclear receptors that act as master regulators of mitochondrial biogenesis and oxidative metabolism. Unlike traditional nuclear receptors, ERRs don’t require a classical ligand to function, which is why developing potent synthetic agonists like SLU-PP-332 represented a significant challenge for medicinal chemists. Published in 2023 in the Journal of Medicinal Chemistry, SLU-PP-332 demonstrated the ability to dramatically upregulate mitochondrial gene networks in preclinical models, producing physiological changes that mirrored aspects of endurance exercise at the molecular level.
What Is Cardarine (GW-501516)?
Cardarine is a PPARδ (peroxisome proliferator-activated receptor delta) agonist first developed in the 1990s by GlaxoSmithKline and Ligand Pharmaceuticals. PPARδ is a nuclear receptor that regulates fatty acid oxidation, glucose homeostasis, and skeletal muscle fiber-type switching. In preclinical research, Cardarine produced marked increases in endurance capacity, fat oxidation, and favorable changes in lipid profiles. Its development as a pharmaceutical was halted after long-term animal toxicology studies raised concerns, but it remains one of the most studied PPAR agonists in the research literature.
Research Overview
The mechanistic rationale for combining SLU-PP-332 and Cardarine lies in the convergence of their target pathways. ERRα (SLU-PP-332’s primary target) and PPARδ (Cardarine’s target) both feed into PGC-1α signaling — the central regulator of mitochondrial biogenesis. ERRα is actually a direct downstream effector of PGC-1α, meaning these two compounds may activate overlapping gene networks through complementary entry points.
Key research references:
- Zuercher et al. (2005) — original characterization of ERR agonist activity: PubMed 16107149
- Wang et al. (2004) — foundational Cardarine/PPARδ endurance research in mice: PubMed 15525938
- SLU-PP-332 primary publication (2023), J. Med. Chem.: ACS Publication
- Narkar et al. (2008) — AMPK + PPARδ “exercise pill” research in Cell: PubMed 18674809
Community discussion of this stack can be found on r/Peptides and r/nootropics, where researchers and biohackers exchange n=1 observations and protocol variations.
Potential Benefits Studied in Preclinical Research
- Mitochondrial biogenesis: SLU-PP-332 upregulates the ERR/PGC-1α gene network, driving the production of new mitochondria — the primary energy-producing organelles in cells.
- Enhanced fatty acid oxidation: Cardarine’s PPARδ activation shifts cellular fuel preference toward fat, sparing glycogen and potentially improving endurance in research models.
- Oxidative muscle fiber switching: Both compounds have been associated with increased expression of slow-twitch (Type I) muscle fiber markers in animal studies, a hallmark of endurance adaptation.
- Improved lipid profiles: Cardarine consistently raised HDL and lowered LDL in primate studies; SLU-PP-332’s effects on lipids are less characterized but under active investigation.
- Metabolic flexibility: The combination may offer complementary effects on how cells switch between fuel sources, a key variable in metabolic disease research.
- VO2 max proxies: In the landmark 2008 Cell paper, sedentary mice given a PPARδ agonist ran 70% farther than controls — a result that generated enormous interest.
Dosage & Administration
Research on SLU-PP-332 is early-stage, with most data from in vitro and rodent models. In murine research, doses have typically been in the 10–30 mg/kg range administered subcutaneously or orally. Human-equivalent dosing extrapolations are speculative and should be treated as such.
Cardarine has a more established preclinical dosing literature. In primate studies, oral doses of 0.1–3 mg/kg were used; the widely cited human research analogs suggest 10–20 mg/day as the range most commonly explored in community research settings, though no approved human dosing exists.
Both compounds are typically administered orally in research settings, though injectable formulations exist for Cardarine. The combination is generally explored with standard doses of each compound rather than modified individual doses, though this remains highly variable across research contexts.
Where to Find It for Research
The SLU-PP-332 + Cardarine combination is available at combatresearch.is for researchers sourcing compounds for study purposes.
Conclusion
The SLU-PP-332 and Cardarine stack represents one of the more mechanistically interesting combinations in current metabolic research. By targeting both ERR nuclear receptors and PPARδ — two nodes in the same upstream network controlling mitochondrial function and fat metabolism — this stack offers a potential dual-pathway approach to studying exercise mimetics and metabolic adaptation. The research is genuinely early, and significant questions remain about human pharmacology, long-term safety, and optimal protocols. That said, for researchers focused on mitochondrial biology, endurance physiology, and metabolic disease, this combination warrants serious investigation.
Disclaimer: This article is for educational and research purposes only. SLU-PP-332 and Cardarine (GW-501516) are research compounds not approved for human use by the FDA or any equivalent regulatory body. Nothing in this article constitutes medical advice. Researchers should consult applicable regulations and institutional guidelines before handling these compounds.
